These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 37964021)
21. Metabolic parameters of [ Markus M; Sartor H; Bjurberg M; Trägårdh E Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676 [TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of interim Lee SY; Seo HJ; Kim S; Eo JS; Oh SC Asia Pac J Clin Oncol; 2018 Oct; 14(5):e302-e309. PubMed ID: 29226597 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [ Glickman A; Paredes P; Carreras-Diéguez N; Niñerola-Baizán A; Gaba L; Pahisa J; Fusté P; Del Pino M; Díaz-Feijóo B; González-Bosquet E; Agustí N; Sánchez-Izquierdo N; Fuster D; Perissinotti A; Romero I; Fernández-Galán E; Carrasco JL; Gil-Ibáñez B; Torné A Eur Radiol; 2022 Apr; 32(4):2200-2208. PubMed ID: 34586465 [TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18 F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma. Mouheb M; Pierre-Jean M; Devillers A; Fermé C; Benchalal M; Manson G; Le Jeune F; Houot R; Palard-Novello X Clin Nucl Med; 2024 Jan; 49(1):e1-e5. PubMed ID: 38015041 [TBL] [Abstract][Full Text] [Related]
25. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166 [TBL] [Abstract][Full Text] [Related]
26. Total tumor burden in lymphoma - an evolving strong prognostic parameter. Meignan M; Cottereau AS; Specht L; Mikhaeel NG Br J Radiol; 2021 Nov; 94(1127):20210448. PubMed ID: 34379496 [TBL] [Abstract][Full Text] [Related]
27. Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy. Watanabe M; Nakamoto Y; Ishimori T; Saga T; Kido A; Hamanishi J; Hamanaka Y; Togashi K Ann Nucl Med; 2020 Feb; 34(2):128-135. PubMed ID: 31768818 [TBL] [Abstract][Full Text] [Related]
28. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411 [TBL] [Abstract][Full Text] [Related]
29. The correlation of Qu YH; Long N; Ran C; Sun J Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540 [TBL] [Abstract][Full Text] [Related]
30. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
31. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma. Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783 [TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma]. Wu LL; Liang JH; Wang L; Xu W; Ding CY Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850 [No Abstract] [Full Text] [Related]
35. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer. Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707 [TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043 [TBL] [Abstract][Full Text] [Related]
37. Metabolic tumour volume in Hodgkin lymphoma-A comparison between manual and AI-based analysis. Sadik M; Barrington SF; Trägårdh E; Saboury B; Nielsen AL; Jakobsen AL; Gongora JLL; Urdaneta JL; Kumar R; Edenbrandt L Clin Physiol Funct Imaging; 2024 May; 44(3):220-227. PubMed ID: 38011940 [TBL] [Abstract][Full Text] [Related]
38. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879 [TBL] [Abstract][Full Text] [Related]
39. Prognostic Role of 2-[ Albano D; Dondi F; Mazzoletti A; Bellini P; Rodella C; Bertagna F Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943426 [TBL] [Abstract][Full Text] [Related]
40. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma. Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]